Astellas 2012 First Quarter Lipitor Sales Down 30%
This article was originally published in PharmAsia News
Astellas announced its first quarter results, and domestic sales of Lipitor, which Astellas produces for Pfizer in Japan, decreased 32.8% as prices of the drug were decreased by 11% when it launched as a generic drug in November 2011.
You may also be interested in...
Novartis has been tipped to regain dominance in AMD, but Bayer/Regeneron have also gained 12-week dosing approval.
Xellia has added a 500mg/100ml variant to its range of vancomycin ready-to-use bags in the US, while Kabi has introduced ertapenem 1g vials and struck a critical-care supply deal with Vizient.